NCT01871558 - Vildagliptin/Metformin in T2DM Patients Starting Basal Insulin | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 30, 2013

Primary Completion Date

February 28, 2015

Study Completion Date

February 28, 2015

Conditions

Type 2 Diabetes Mellitus (T2DM)

Interventions

DRUG

Vildagliptin

50 mg b.i.d

DRUG

Metformin

metformin is to be kept unchanged

DRUG

sulfonylurea (SU)

DRUG

Basal Insulin

Trial Locations (19)

14000

Novartis Investigative Site, Caen

14123

Novartis Investigative Site, Fleury-sur-Orne

26000

Novartis Investigative Site, Valence

29200

Novartis Investigative Site, Brest

31300

Novartis Investigative Site, Toulouse

34090

Novartis Investigative Site, Montpellier

35203

Novartis Investigative Site, Rennes

44600

Novartis Investigative Site, Saint-Nazaire

55012

Novartis Investigative Site, Bar-le-Duc

59300

Novartis Investigative Site, Valenciennes

67000

Novartis Investigative Site, Strsbourg

75010

Novartis Investigative Site, Paris

78600

Novartis Investigative Site, Maisons-Laffitte

83110

Novartis Investigative Site, Sanary-sur-Mer

89000

Novartis Investigative Site, Auxerre

91100

Novartis Investigative Site, Corbeil-Essonnes

93143

Novartis Investigative Site, Bondy

06600

Novartis Investigative Site, Antibes

06500

Novartis Investigative Site, Menton